Supernus Pharmaceuticals (SUPN) PT Raised to $16 at Piper Jaffray Post Q4

March 12, 2015 7:21 AM

Piper Jaffray analyst David Amsellem reiterated an Overweight rating and boosted his price target on Supernus Pharmaceuticals (NASDAQ: SUPN) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found